Related Experiment Video

Updated: Jun 28, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors

Patricia Kruchten1, Ruth Werth, Sandrine Marchais-Oberwinkler

  • 18.2 Pharmaceutical and Medicinal Chemistry, Saarland University, PO Box 15 11 50, D-66041 Saarbrücken, Germany.

Molecular and Cellular Endocrinology
|November 6, 2008
PubMed

Insights

Researchers developed a new screening system to find inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). This enzyme is crucial in estrogen-dependent cancers, and the system identified four potent compounds for potential therapeutic use.

Area of Science:

  • Biochemistry
  • Enzyme kinetics
  • Pharmacology

Background:

  • 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) catalyzes the conversion of estrone (E1) to estradiol (E2).
  • Estradiol (E2) plays a significant role in the development and progression of estrogen-dependent diseases like breast cancer and endometriosis.
  • Overexpression of 17beta-HSD1 in these diseases suggests it as a potential therapeutic target.

Purpose of the Study:

  • To develop an efficient and reliable screening system for identifying 17beta-HSD1 inhibitors.
  • To discover potent and selective 17beta-HSD1 inhibitors for potential therapeutic applications.

Main Methods:

  • Development of a novel screening system.
  • Screening of an in-house library of potential 17beta-HSD1 inhibitors.

Main Results:

  • Successful development and application of the screening system.
  • Identification of four potent and selective 17beta-HSD1 inhibitors.
  • The identified compounds demonstrated a favorable initial pharmacokinetic profile.

Conclusions:

  • The developed screening system is effective for identifying 17beta-HSD1 inhibitors.
  • The identified compounds represent promising candidates for further development as targeted therapies for estrogen-dependent diseases.

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...